Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315632 | 0.89 | LTA4H (0.47) | FKBP1AGAALTA4HPOLBALDH1A1 | |
| SCHEMBL8977442 | 0.89 | LTA4H (0.47) | FKBP1AGAALTA4HPOLBALDH1A1 | |
| SCHEMBL12677313 | 0.89 | LTA4H (0.47) | FKBP1AGAALTA4HPOLBALDH1A1 | |
| SCHEMBL24960953 | 0.87 | FKBP1A (0.52) | FKBP1ALTA4HPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15114560 | 0.87 | FKBP1A (0.52) | FKBP1ALTA4HPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL24960955 | 0.87 | FKBP1A (0.52) | FKBP1ALTA4HPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL2770438 | 0.85 | FKBP1A (0.47) | FKBP1AGAACYP3A4MAPTTP53 | |
| SCHEMBL2772098 | 0.82 | GBA2 (0.45) | FKBP1AGAACYP3A4MAPTLTA4H | |
| SCHEMBL13403377 | 0.79 | SMN1; SMN2 (0.36) | GAACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2772351 | 0.79 | CYP19A1 (0.43) | FKBP1ATP53LTA4HPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-1316610-B1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6936445-B2 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1201653-B1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL CO (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-0957089-B1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-20030124683-A1 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1316610-A1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| EP-1201653-A1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6166224-A | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0957089-A1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | FKBP1A 3293/4885GAA 513/4885CYP3A4 4882/4885 |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | FKBP1A 542/4885GAA 2864/4885CYP3A4 4456/4885 |
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | FKBP1A 800/4885GAA 2267/4885CYP3A4 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.